Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00887315 · ClinicalTrials.gov registry record · Phase 2
The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00887315 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 11 participants.
The verdict
NCT00887315, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
Primary goal of the study is to assess the overall survival of the addition of hypofractionated image guided radiotherapy concurrently with Docetaxel and cisplatin. Survival will be assessed at 1 year from the date of study enrollment to date of death.
Interventions
- DRUG Docetaxel and cisplatin
- RADIATION Docetaxel and cisplatin Plus Hypofractionated Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00887315
The ClinicalTrials.gov registry entry for NCT00887315 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel and cisplatin is the first listed.
NCT00887315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00887315 about?
NCT00887315 is a clinical study titled "The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)". Primary goal of the study is to assess the overall survival of the addition of hypofractionated image guided radiotherapy concurrently with Docetaxel and cisplatin. Survival will be assessed at 1 year from the date of study enrollment to date of death.
What is the current status of trial NCT00887315?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2009-04. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00887315?
The interventions under investigation include: Docetaxel and cisplatin (DRUG), Docetaxel and cisplatin Plus Hypofractionated Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT00887315?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.